PetMeds® Announces Second Quarter Fiscal 2025 Financial Results

Rhea-AI Summary

PetMed Express (NASDAQ: PETS) reported its Q2 fiscal 2025 financial results with net sales of $59.6 million and a gross margin of 29.1%, up 0.8% year-over-year. The company posted net income of $2.3 million, or $0.11 per diluted share, compared to $0.7 million, or $0.03 per diluted share, in the prior year period. Adjusted EBITDA reached $2.1 million, improving from a loss of $(1.5) million in Q1 fiscal 2025, though down from $3.4 million year-over-year. The company highlighted progress in its business transformation, including consolidation of operations and cost structure improvements.

Positive

• Net income increased to $2.3 million from $0.7 million year-over-year
• Gross margin improved by 0.8% compared to prior year
• Sequential improvement in Adjusted EBITDA from -$1.5M to $2.1M

Negative

• Adjusted EBITDA decreased from $3.4M to $2.1M year-over-year

Insights

Financial Analyst

PETS delivered mixed Q2 results with notable improvements in profitability metrics. Net sales reached $59.6 million, while gross margin expanded by 0.8% to 29.1%. The company's net income tripled to $2.3 million ($0.11 per share) from $0.7 million ($0.03 per share) year-over-year. The significant sequential improvement in Adjusted EBITDA from a $1.5 million loss to $2.1 million profit signals successful cost-cutting measures.

The operational consolidation between PetMeds and PetCareRX appears to be yielding positive results in cost reduction, though still below last year's Adjusted EBITDA of $3.4 million. The company's focus on profitability improvement through operational streamlining demonstrates a pragmatic approach to business transformation, setting a foundation for future growth initiatives in product assortment and marketing.

DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2024.

Second Quarter Fiscal 2025 Financial Highlights

• Net sales of $59.6 million.
  
• Gross margin of 29.1%, an increase of 0.8% compared to the prior year period.
  
• Net income of $2.3 million, or $0.11 per diluted share, compared to net income of $0.7 million, or $0.03 per diluted share, in the prior year period.  
  
• Adjusted EBITDA of $2.1 million improved sequentially from an Adjusted EBITDA loss of $(1.5) million in the first quarter of fiscal 2025 and compared to Adjusted EBITDA of $3.4 million in the prior year period.
  
• Continued progress on key initiatives supporting the transformation of the business.
  

“We demonstrated significant progress on key initiatives of phase one of our transformation, aimed at improving profitability during the second quarter while also advancing our vision of being a leader in the consumer pet healthcare sector,” said Sandra Campos, CEO & President.   “By consolidating and streamlining our PetMeds and PetCareRX back-of-the-house operations, we’ve materially lowered our cost structure, which helped us deliver a strong sequential improvement in Adjusted EBITDA during the second quarter.   We are now well positioned to lean more aggressively into differentiating product assortments, brand awareness campaigns, and core marketing initiatives to drive growth. While it’s still very early in our turnaround, we remain confident in our direction and belief that the changes and investments we are making across our business will create a more compelling, enduring value proposition for all stakeholders and will significantly strengthen our competitive position.”

This afternoon the Company will host a conference call to review the quarter’s financial results.

Time: 4:30 P.M. Eastern Time, November 6, 2024

Public call dial in (877) 407-0789 (toll free) or (201) 689-8562.

Webcast stream link: https://investors.petmeds.com for those who wish to stream the call via webcast.

Replay: Available until November 20, 2024, at 11:59 P.M Eastern Time.

To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 13748837.

About PetMed Express, Inc.

Founded in 1996, PetMeds is a leader in the consumer pet healthcare sector. As a national online retailer with expert pharmacists and licenses across fifty states, PetMeds.com and PetCareRx.com deliver top branded pharmaceuticals, generics, compounded prescription medications and OTC supplements and vitamins that help pets live longer, healthier lives. Leveraging telehealth and insurance partnerships, they offer unparalleled value and convenience that enhance wellness and longevity for dogs, cats, and horses. PetMeds and PetCareRx provides essential pet health offerings through their websites, www.PetMeds.com and www.PetCareRx.com.

Forward Looking Statement

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan.   Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

PETMEDS INVESTOR RELATIONS CONTACT
ICR, LLC
John Mills
(646) 277-1254

Reed Anderson
(646) 277-1260
investor@petmeds.com

PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share data)
	September 30, 2024				March 31, 2024
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	52,045			$	55,296
Accounts receivable, less allowance for credit losses of $27 and $273, respectively		1,620				3,283
Inventories, net		13,092				28,556
Prepaid expenses and other current assets		3,655				6,325
Prepaid income taxes		367				188
Total current assets		70,779				93,648
Noncurrent assets:
Property and equipment, net		26,204				26,657
Intangible and other assets, net		15,524				16,503
Goodwill		26,658				26,658
Operating lease right-of-use assets		1,188				1,432
Deferred tax assets, net		5,681				4,986
Total noncurrent assets		75,255				76,236
Total assets	$	146,034			$	169,884
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	16,951			$	37,024
Sales tax payable		24,373				25,012
Accrued expenses and other current liabilities		5,412				7,060
Current operating lease liabilities		446				459
Deferred revenue		1,650				2,603
Total current liabilities		48,832				72,158
Operating lease liabilities, net of current lease liabilities		768				995
Total liabilities		49,600				73,153
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share		9				9
Common stock, $.001 par value, 40,000,000 shares authorized; 20,663,218 and 21,148,692 shares issued and outstanding, respectively		21				21
Additional paid-in capital		17,515				25,146
Retained earnings		78,889				71,555
Total shareholders' equity		96,434				96,731
Total liabilities and shareholders' equity	$	146,034			$	169,884

PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except for share and per share amounts) (Unaudited)
	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
Net sales	$	59,570			$	70,999			$	127,522			$	149,243
Cost of sales		42,259				50,937				92,240				106,655
Gross profit		17,311				20,062				35,282				42,588
Operating expenses:
General and administrative		10,493				11,962				15,367				27,673
Advertising		4,606				5,512				11,596				12,777
Depreciation and amortization		1,658				1,713				3,379				3,391
Total operating expenses		16,757				19,187				30,342				43,841
Income (loss) from operations		554				875				4,940				(1,253	)
Other income:
Interest income, net		185				151				280				345
Other, net		186				254				417				760
Total other income		371				405				697				1,105
Income (loss) before (benefit) provision for income taxes		925				1,280				5,637				(148	)
(Benefit) provision for income taxes		(1,401	)			565				(443	)			273
Net income (loss)	$	2,326			$	715			$	6,080			$	(421	)
Net income (loss) per common share:
Basic	$	0.11			$	0.04			$	0.30			$	(0.02	)
Diluted	$	0.11			$	0.03			$	0.29			$	(0.02	)
Weighted average number of common shares outstanding:
Basic		20,597,807				20,382,979				20,555,544				20,357,752
Diluted		20,938,817				20,780,455				20,940,161				20,357,752
Cash dividends declared per common share	$	—			$	0.30			$	—			$	0.60

PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
	Six Months Ended September 30,
	2024				2023
Cash flows from operating activities:
Net income (loss)	$	6,080			$	(421	)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization		3,379				3,391
Share based compensation		(7,631	)			3,489
Deferred income taxes		(696	)			(146	)
Bad debt expense		176				36
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable		1,488				(345	)
Inventories, net		15,464				3,237
Prepaid income taxes		(179	)			426
Prepaid expenses and other current assets		2,670				(3,516	)
Operating lease right-of-use assets, net		245				394
Accounts payable		(20,071	)			(5,542	)
Sales tax payable		(639	)			(1,278	)
Accrued expenses and other current liabilities		(221	)			(136	)
Lease liabilities		(240	)			(383	)
Deferred revenue		(953	)			579
Net cash (used in) provided by operating activities	$	(1,128	)		$	(215	)
Cash flows from investing activities:
Acquisition of PetCareRx, net of cash acquired		–				(35,859	)
Purchases of property and equipment		(1,948	)			(2,137	)
Net cash used in investing activities	$	(1,948	)		$	(37,996	)
Cash flows from financing activities:
Dividends paid		(175	)			(12,404	)
Net cash used in financing activities	$	(175	)		$	(12,404	)
Net decrease in cash and cash equivalents		(3,251	)			(50,615	)
Cash and cash equivalents, at beginning of period		55,296				104,086
Cash and cash equivalents, at end of period	$	52,045			$	53,471
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	466			$	–
Dividends payable in accrued expenses and other current liabilities	$	39			$	1,513

Non-GAAP Financial Measures

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

• Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
• Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
• Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
• Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
• Adjusted EBITDA does not reflect certain expenses including the estimated state sales tax accrual which reduces cash available to us.
• Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.

Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated:

Reconciliation of Non-GAAP Measures PetMed Express, Inc. (Unaudited)
	Three Months Ended								Increase (Decrease)
($ in thousands, except percentages)	September 30, 2024				September 30, 2023				$				%
Consolidated Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA:
Net income	$	2,326			$	715			$	1,611			225	%
Add (subtract):
Stock-based Compensation	$	573			$	1,728			$	(1,155	)		(67	)%
Income Taxes	$	(1,401	)		$	565			$	(1,966	)		(348	)%
Depreciation and Amortization	$	1,658			$	1,713			$	(55	)		(3	)%
Interest (Income), Net(1)	$	(185	)		$	(151	)		$	(34	)		23	%
Acquisition/Partnership Transactions and Other Items	$	–			$	168			$	(168	)		(100	)%
Employee Severance	$	305			$	15			$	290			1933	%
Sales Tax (Income)	$	(1,178	)		$	(1,316	)		$	138			(10	)%
Adjusted EBITDA	$	2,098			$	3,437			$	(1,339	)		(39	)%

(1) Included in interest income, net is $0.4 million of interest expense related to the sales tax liability and $0.6 million of interest income for the three months ended September 30, 2024. This compares to $0.4 million of interest expense related to the sales tax liability and $0.6 million of interest income for the three months ended September 30, 2023.

	Six Months Ended								Increase (Decrease)
($ in thousands, except percentages)	September 30, 2024				September 30, 2023				$				%
Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:
Net income	$	6,080			$	(421	)		$	6,501			(1544	)%
Add (subtract):
Stock-based Compensation	$	(7,631	)		$	3,488			$	(11,119	)		(319	)%
Income Taxes	$	(443	)		$	273			$	(716	)		(262	)%
Depreciation and Amortization	$	3,379			$	3,391			$	(12	)		—	%
Interest (Income), Net (1)	$	(280	)		$	(345	)		$	65			(19	)%
Acquisition/Partnership Transactions and Other Items	$	180			$	1,294			$	(1,114	)		(86	)%
Employee Severance	$	454			$	408			$	46			11	%
Sales Tax (Income)	$	(1,178	)		$	(1,316	)		$	138			(10	)%
Adjusted EBITDA	$	561			$	6,772			$	(6,211	)		(92	)%

(1) Included in interest income, net is $0.8 million of interest expense related to the sales tax liability and $1.1 million of interest income for the six months ended September 30, 2024. This compares to $0.8 million of interest expense related to the sales tax liability and $1.2 million of interest income for the six months ended September 30, 2023.

FAQ

What was PetMeds (PETS) Q2 2025 net income?

PetMeds reported a net income of $2.3 million, or $0.11 per diluted share, for Q2 fiscal 2025.

How much did PetMeds (PETS) gross margin improve in Q2 2025?

PetMeds' gross margin increased by 0.8% to 29.1% compared to the prior year period.

What was PetMeds (PETS) Q2 2025 Adjusted EBITDA?

PetMeds reported Adjusted EBITDA of $2.1 million, improving from a loss of $1.5 million in Q1 2025 but down from $3.4 million in the prior year period.